However, animal models showed, that while collagen- and GPIb-binding are essential in stroke development, GPIIbIIIa interactions are without any relevance.151The insignificant effect of vWF-GPIIbIIIa binding in stroke is therefore compatible with the negative clinical trials of the GPIIbIIIa receptor inhibitor Abciximab.8Thus, only GPIb-vWF and collagen-vWF blockers are in the focus of drug development for stroke. The gene discussed is VWF; the disease is stroke disorder.